other material
confidence high
sentiment positive
materiality 0.90
Lorundrostat meets primary endpoints in Launch-HTN Phase 3 & Advance-HTN Phase 2 with significant BP reduction
Mineralys Therapeutics, Inc.
- Launch-HTN Phase 3: 50 mg lorundrostat achieved 9.1 mmHg placebo-adjusted SBP reduction (p<0.0001) at week 6 and 11.7 mmHg at week 12.
- Advance-HTN Phase 2: 50 mg achieved 7.9 mmHg placebo-adjusted SBP reduction by 24hr ABPM at week 12 (p<0.0001).
- Safety profile favorable: SAEs 2.2% (50 mg) vs 3.0% placebo; hyperkalemia (>6.0 mmol/L) 1.1% in Launch-HTN, 5.3% in Advance-HTN.
- Diverse enrollment: Launch-HTN 47% women, 29% Black/African American; Advance-HTN 40% women, 50% Black/African American.
- Full Advance-HTN results to be presented at ACC Scientific Sessions on March 29, 2025.